LANTERN PHARMA INC (LTRN) Stock News

USA - NASDAQ:LTRN - US51654W1018 - Common Stock

3.2899 USD

+0.08 (+2.49%)

Last: 11/19/2025, 2:56:20 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

LTRN Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Lantern Pharma Inc.

Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

6 days ago - By: Benzinga - Mentions: MGNX MRSN CMND ARDT ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

7 days ago - By: Benzinga

Lantern Pharma Earnings Preview

11 days ago - By: ACCESS Newswire

New to The Street to Broadcast Show Number 698 on Bloomberg - Saturday, November 8, 2025, at 6:30 PM EST

12 days ago - By: ACCESS Newswire

Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows

13 days ago - By: Lantern Pharma Inc.

Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET

20 days ago - By: Lantern Pharma Inc.

Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT

22 days ago - By: Lantern Pharma Inc.

Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.

a month ago - By: Lantern Pharma Inc.

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025

2 months ago - By: ACCESS Newswire - Mentions: ENLV

Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

2 months ago - By: Lantern Pharma Inc.

Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors

3 months ago - By: Lantern Pharma Inc.

Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial

3 months ago - By: ACCESS Newswire

RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26

3 months ago - By: The Motley Fool

Lantern Pharma Narrows Loss in Q2

3 months ago - By: Lantern Pharma Inc.

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

4 months ago - By: Lantern Pharma Inc.

Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

4 months ago - By: Lantern Pharma Inc.

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

4 months ago - By: Lantern Pharma Inc.

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

4 months ago - By: Lantern Pharma Inc.

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

4 months ago - By: ACCESS Newswire

Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

4 months ago - By: Lantern Pharma Inc.

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

4 months ago - By: Lantern Pharma Inc.

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy

4 months ago - By: Lantern Pharma Inc.

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

5 months ago - By: Lantern Pharma Inc.

Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

6 months ago - By: Yahoo Finance - Mentions: REVB ESLT CTKB KROS ...

Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering

6 months ago - By: Yahoo Finance - Mentions: VREX CTKB KROS CADL ...

Varex Imaging Corporation (VREX) Downgraded by S&P as Regulatory Outlook Remains Cloudy

6 months ago - By: Lantern Pharma Inc.

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

6 months ago - By: Lantern Pharma Inc.

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

6 months ago - By: Lantern Pharma Inc.

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

7 months ago - By: Lantern Pharma Inc.

Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET